M2- L11: Rheumatoid Arthritis and Tuberculosis: TB Screening Protocols Before Starting Biologics

Biologic and targeted synthetic DMARDs used in rheumatoid arthritis suppress the exact immune pathways that normally keep a dormant TB infection contained, so starting these drugs can reactivate latent tuberculosis into active disease. This lecture covers who needs screening before biologics, how to choose and interpret TST versus IGRA testing, when a chest X-ray is needed, when isoniazid prophylaxis should be started and for how long before biologic therapy begins, and how screening priorities shift across anti-TNF agents, IL-6 inhibitors, JAK inhibitors, and newer biologic classes — with special attention to practical screening in TB-endemic settings like Pakistan. Medical Disclaimer The content of this video is intended for educational and informational purposes only, specifically for medical students, trainees, and healthcare professionals. It does not constitute individual medical advice, diagnosis, or treatment. While every effort is made to ensure clinical accuracy, medical knowledge is constantly evolving. Viewers should always consult a qualified healthcare provider for personal health concerns. The creator of this series assumes no liability for actions taken based on the information provided herein. Rheumatology Master Class By Rheumatologist Dr Muhammad Waqar Khan #RheumatologistDrMuhammadWaqarKhan #DrWaqarKhan #RheumatologyFellowship #RheumatologyLectures #RheumatoidArthritis #SLE #Lupus #Gout #AnkylosingSpondylitis #Ostearthritis #Osteoporosis #MCTD #SystemicSclerosis #ACR #EULAR #BSR #PSR #RheumatologyTraining #MedicalEducationPakistan